Akero Therapeutics Inc Stock
Akero Therapeutics Inc Stock
There is an upward development for Akero Therapeutics Inc compared to yesterday, with an increase of €0.000 (2.720%).
With 14 Buy predictions and not the single Sell prediction the community is currently very high on Akero Therapeutics Inc.
With a target price of 38 € there is potential for a 118.89% increase which would mean more than doubling the current price of 17.36 € for Akero Therapeutics Inc.
Our community identified positive and negative aspects for Akero Therapeutics Inc stock for the coming years. 2 users see the criterium "Revenue growth" as a plus for the Akero Therapeutics Inc stock. On the other hand our users think that "Worthwhile Investment for the next years" could be a problem in the future.
Pros and Cons of Akero Therapeutics Inc in the next few years
Pros
?
M***** P*******
?
S********** s********
?
C******** o* t** e**********
Cons
?
W********* I********* f** t** n*** y****
?
B****
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Akero Therapeutics Inc vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
Akero Therapeutics Inc | 2.720% | 2.813% | -11.043% | -60.365% | -20.367% | - | - |
Evolus Inc | 2.610% | 2.609% | 0.000% | 44.785% | 30.387% | 26.203% | - |
Ardelyx Inc. | 3.070% | 1.608% | 0.032% | 93.211% | 9.308% | 11.823% | - |
Salarius Pharmaceuticals Inc. | - | -3.015% | -16.087% | -67.833% | -30.450% | -98.515% | -99.994% |
Comments
Akero Therapeutics, Inc. (NASDAQ: AKRO) had its price target lowered by analysts at Evercore ISI from $50.00 to $38.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for AKRO provided by MarketBeat
Akero Therapeutics, Inc. (NASDAQ: AKRO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $50.00 price target on the stock.
Show more
Ratings data for AKRO provided by MarketBeat
Akero Therapeutics, Inc. (NASDAQ: AKRO) had its price target raised by analysts at UBS Group AG from $39.00 to $42.00. They now have a "buy" rating on the stock.
Show more
Ratings data for AKRO provided by MarketBeat